Clinical experimentation with aerosol antibiotics: current and future methods of administration

References

• Zhang L Huang Y Zhou Y Buckley T Wang HH Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota Antimicrob Agents Chemother 2013 57 8 3659 3666 23689712
   PubMed Web of Science ®Google Scholar
• Young SW Zhang M Freeman JT Mutu-Grigg J Pavlou P Moore GA The Mark Coventry Award: higher tissue concentrations of vancomycin with low-dose intraosseous regional versus systemic prophylaxis in TKA: a randomized trial Clin Orthop Relat Res 5 11 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Smaldone GC Advances in aerosols: adult respiratory disease J Aerosol Med 2006 19 1 36 46 16551213
   PubMedGoogle Scholar
• Houtmeyers E Gosselink R Gayan-Ramirez G Decramer M Regulation of mucociliary clearance in health and disease Eur Respir J 1999 13 5 1177 1188 10414423
   PubMed Web of Science ®Google Scholar
• Clay MM Pavia D Newman SP Clarke SW Factors influencing the size distribution of aerosols from jet nebulisers Thorax 1983 38 10 755 759 6648854
   PubMed Web of Science ®Google Scholar
• Smith EC Denyer J Kendrick AH Comparison of twenty three nebulizer/compressor combinations for domiciliary use Eur Respir J 1995 8 7 1214 1221 7589407
   PubMed Web of Science ®Google Scholar
• Douglas JG Leslie MJ Crompton GK Grant IW Is the flow rate used to drive a jet nebuliser clinically important? Br Med J (Clin Res Ed) 1985 290 6461 29
   Google Scholar
• Newman SP Pellow PG Clay MM Clarke SW Evaluation of jet nebulisers for use with gentamicin solution Thorax 1985 40 9 671 676 4060108
   PubMed Web of Science ®Google Scholar
• Byron PR Aerosol formulation, generation and delivery using non-metered systems Respiratory Drug Delivery Boca Raton, FL CRC Press 1990
   Google Scholar
• Kendrick AH Smith EC Denyer J Nebulizers – fill volume, residual volume and matching of nebulizer to compressor Respir Med 1995 89 3 157 159 7746906
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Kioumis I Ritzoulis C New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam Int J Pharm 7 23 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Kendrick AH Smith EC Wilson RS Selecting and using nebuliser equipment Thorax 1997 52 Suppl 2 S92 S101 9155861
   PubMed Web of Science ®Google Scholar
• Kwok PC Trietsch SJ Kumon M Chan HK Electrostatic charge characteristics of jet nebulized aerosols J Aerosol Med Pulm Drug Deliv 2010 23 3 149 159 20500092
   PubMed Web of Science ®Google Scholar
• Davis SS Bubb MD Physico-chemical studies on aerosol solutions for drug delivery. 3 The effect of relative humidity on the particle size of inhalation aerosols Int J Pharm 1978 6 1 303 314
   Web of Science ®Google Scholar
• Davis SS Warburton B Physico-chemical studies on aerosol solutions for drug delivery. I. Water-propylene glycol studies Int J Pharm 1978 1 71 83
   Web of Science ®Google Scholar
• Newman SP Pellow PGD Clarke SW Drop sizes from medical atomisers (nebulisers) for drug solutions of different viscosities and surface tensions Atom Spray Technol 1987 3 1 11
   Google Scholar
• Labiris NR Dolovich MB Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications Br J Clin Pharmacol 2003 56 6 588 599 14616418
   PubMed Web of Science ®Google Scholar
• Nunn JF Nunn’s Applied Respiratory Physiology 4th ed Oxford, UK Butterworth-Heineman 1993
   Google Scholar
• Zarogoulidis P Papanas N Kouliatsis G Spyratos D Zarogoulidis K Maltezos E Inhaled insulin: too soon to be forgotten? J Aerosol Med Pulm Drug Deliv 2011 24 5 213 223 21689020
   PubMed Web of Science ®Google Scholar
• Suresh Babu K Kastelik J Morjaria JB Role of long term antibiotics in chronic respiratory diseases Respir Med 2013 107 6 800 815 23522403
   PubMed Web of Science ®Google Scholar
• Togami K Chono S Morimoto K Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections J Aerosol Med Pulm Drug Deliv 2012 25 2 110 115 22360316
   PubMed Web of Science ®Google Scholar
• Otterson GA Villalona-Calero MA Hicks W Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer Clin Cancer Res 2010 16 8 2466 2473 20371682
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Eleftheriadou E Sapardanis I Feasibility and effectiveness of inhaled carboplatin in NSCLC patients Invest New Drugs 2012 30 4 1628 1640 21739158
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Chatzaki E Porpodis K Inhaled chemotherapy in lung cancer: future concept of nanomedicine Int J Nanomedicine 2012 7 1551 1572 22619512
   PubMed Web of Science ®Google Scholar
• Darwiche K Zarogoulidis P Karamanos NK Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology Future Oncol 2013 9 4 505 525 23560374
   PubMed Web of Science ®Google Scholar
• Geller DE Pitlick WH Nardella PA Tracewell WG Ramsey BW Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis Chest 2002 122 1 219 226 12114362
   PubMed Web of Science ®Google Scholar
• Ramsey BW Pepe MS Quan JM Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group N Engl J Med 1999 340 1 23 30 9878641
   PubMed Web of Science ®Google Scholar
• Moss RB Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis Chest 2002 121 1 55 63 11796432
   PubMed Web of Science ®Google Scholar
• Moss RB Administration of aerosolized antibiotics in cystic fibrosis patients Chest 2001 120 Suppl 3 107S 113S 11555564
   PubMed Web of Science ®Google Scholar
• Murphy TD Anbar RD Lester LA Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease Pediatr Pulmonol 2004 38 4 314 320 15334509
   PubMed Web of Science ®Google Scholar
• Geller DE Madge S Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis Respir Med 2011 105 Suppl 2 S24 S31 22208547
   PubMed Web of Science ®Google Scholar
• Chuchalin A Csiszer E Gyurkovics K A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study Paediatr Drugs 2007 9 Suppl 1 21 31 17536872
   PubMedGoogle Scholar
• Flume PA O’Sullivan BP Robinson KA Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health Am J Respir Crit Care Med 2007 176 10 957 969 17761616
   PubMed Web of Science ®Google Scholar
• Gibson RL Retsch-Bogart GZ Oermann C Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis Pediatr Pulmonol 2006 41 7 656 665 16703579
   PubMed Web of Science ®Google Scholar
• Retsch-Bogart GZ Burns JL Otto KL A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection Pediatr Pulmonol 2008 43 1 47 58 18041081
   PubMed Web of Science ®Google Scholar
• Retsch-Bogart GZ Quittner AL Gibson RL Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis Chest 2009 135 5 1223 1232 19420195
   PubMed Web of Science ®Google Scholar
• McCoy KS Quittner AL Oermann CM Gibson RL Retsch-Bogart GZ Montgomery AB Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis Am J Respir Crit Care Med 2008 178 9 921 928 18658109
   PubMed Web of Science ®Google Scholar
• Oermann CM Retsch-Bogart GZ Quittner AL An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis Pediatr Pulmonol 2010 45 11 1121 1134 20672296
   PubMed Web of Science ®Google Scholar
• Oermann CM McCoy KS Retsch-Bogart GZ Gibson RL McKevitt M Montgomery AB Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI) J Antimicrob Chemother 2011 66 10 2398 2404 21784781
   PubMed Web of Science ®Google Scholar
• Wainwright CE Quittner AL Geller DE Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa J Cyst Fibros 2011 10 4 234 242 21441078
   PubMed Web of Science ®Google Scholar
• Hansen CR Pressler T Hoiby N Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience J Cyst Fibros 2008 7 6 523 530 18693078
   PubMed Web of Science ®Google Scholar
• Jensen T Pedersen SS Garne S Heilmann C Hoiby N Koch C Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Antimicrob Chemother 1987 19 6 831 838 3301785
   PubMed Web of Science ®Google Scholar
• Hodson ME Gallagher CG Govan JR A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Eur Respir J 2002 20 3 658 664 12358344
   PubMed Web of Science ®Google Scholar
• Heijerman H Westerman E Conway S Touw D Doring G Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus J Cyst Fibros 2009 8 5 295 315 19559658
   PubMed Web of Science ®Google Scholar
• Beringer P The clinical use of colistin in patients with cystic fibrosis Curr Opin Pulm Med 2001 7 6 434 440 11706322
   PubMedGoogle Scholar
• McCoy KS Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome N Engl J Med 2007 357 22 2310 2311 18046039
   PubMed Web of Science ®Google Scholar
• European Medicines’ Agency Colobreathe Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001225/smops/Positive/human_smop_000270.jsp&mid=WC0b01ac058001d127&jsenabled=true Accessed August 23, 2013
   Google Scholar
• Geller DE Weers J Heuerding S Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology J Aerosol Med Pulm Drug Deliv 2011 24 4 175 182 21395432
   PubMed Web of Science ®Google Scholar
• Geller DE Konstan MW Smith J Noonberg SB Conrad C Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr Pulmonol 2007 42 4 307 313 17352404
   PubMed Web of Science ®Google Scholar
• Konstan MW Flume PA Kappler M Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial J Cyst Fibros 2011 10 1 54 61 21075062
   PubMed Web of Science ®Google Scholar
• PARI Pharma GmbH eFlow® Technology Advanced Aerosol Delivery Platform Starnberg, Germany PARI Pharma GmbH 2011 Available from: http://www.paripharma.com Accessed August 25, 2013
   Google Scholar
• Insmed Incorporated Arikace® (Inhaled liposomal amikacin) Monmouth Junction, NJ Insmed Incorporated 2011 Available from: http://www.insmed.com/arikace.php#p1 Accessed August 25, 2013
   Google Scholar
• Meers P Neville M Malinin V Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections J Antimicrob Chemother 2008 61 4 859 868 18305202
   PubMed Web of Science ®Google Scholar
• King P Lomovskaya O Griffith DC Burns JL Dudley MN In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis Antimicrob Agents Chemother 2010 54 1 143 148 19805554
   PubMed Web of Science ®Google Scholar
• King P Citron DM Griffith DC Lomovskaya O Dudley MN Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients Diagn Microbiol Infect Dis 2010 66 2 181 186 19828274
   PubMed Web of Science ®Google Scholar
• Trapnell BC McColley SA Kissner DG Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection Am J Respir Crit Care Med 2012 185 2 171 178 22095545
   PubMed Web of Science ®Google Scholar
• Son YJ McConville JT A new respirable form of rifampicin Eur J Pharm Biopharm 2011 78 3 366 376 21324356
   PubMed Web of Science ®Google Scholar
• Ong HX Traini D Cipolla D Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia Pharm Res 2012 29 12 3335 3346 22833052
   PubMed Web of Science ®Google Scholar
• Durand M Pourchez J Aubert G Impact of acoustic airflow nebulization on intrasinus drug deposition of a human plastinated nasal cast: new insights into the mechanisms involved Int J Pharm 2011 421 1 63 71 21963472
   PubMed Web of Science ®Google Scholar
• Willis LD Berlinski A Survey of aerosol delivery techniques to spontaneously breathing tracheostomized children Respir Care 2012 57 8 1234 1241 22348743
   PubMed Web of Science ®Google Scholar
• McCormack P McNamara PS Southern KW A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis J Cyst Fibros 2011 10 5 343 349 21620782
   PubMed Web of Science ®Google Scholar
• Parkins MD Elborn JS Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis Expert Rev Respir Med 2011 5 5 609 622 21955231
   PubMed Web of Science ®Google Scholar
• Pourshahab PS Gilani K Moazeni E Eslahi H Fazeli MR Jamalifar H Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid J Microencapsul 2011 28 7 605 613 21793647
   PubMed Web of Science ®Google Scholar
• Chan JG Chan HK Prestidge CA Denman JA Young PM Traini D A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics Eur J Pharm Biopharm 9 13 2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Chuealee R Wiedmann TS Srichana T Physicochemical properties and antifungal activity of amphotericin B incorporated in cholesteryl carbonate esters J Pharm Sci 2011 100 5 1727 1735 21374610
   PubMed Web of Science ®Google Scholar
• Nasr M Nawaz S Elhissi A Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization Int J Pharm 2012 436 1–2 611 616 22842623
   PubMed Web of Science ®Google Scholar
• Zhang Y Wang X Lin X Liu X Tian B Tang X High azithromycin loading powders for inhalation and their in vivo evaluation in rats Int J Pharm 2010 395 1–2 205 214 20595022
   PubMed Web of Science ®Google Scholar
• Parkins MD Elborn JS Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis Expert Rev Respir Med 2010 4 4 435 444 20658904
   PubMedGoogle Scholar
• Gilani K Moazeni E Ramezanli T Amini M Fazeli MR Jamalifar H Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulization J Pharm Sci 2011 100 1 252 259 20602350
   PubMed Web of Science ®Google Scholar
• Son YJ McConville JT Preparation of sustained release rifampicin microparticles for inhalation J Pharm Pharmacol 2012 64 9 1291 1302 22881441
   PubMed Web of Science ®Google Scholar
• Abdulla JM Tan YT Darwis Y Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization AAPS PharmSciTech 2010 11 2 663 671 20405256
   PubMed Web of Science ®Google Scholar
• Alexander BD Winkler TP Shi S Dodds Ashley ES Hickey AJ In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols Pharm Dev Technol 2011 16 6 577 582 21699390
   PubMed Web of Science ®Google Scholar
• Stelmach I Korzeniewska A Stelmach W Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland Respiration 2008 75 2 178 181 17435382
   PubMed Web of Science ®Google Scholar
• Briesacher BA Quittner AL Saiman L Sacco P Fouayzi H Quittell LM Adherence with tobramycin inhaled solution and health care utilization BMC Pulm Med 2011 11 5 21251275
   PubMed Web of Science ®Google Scholar
• Konstan MW Geller DE Minic P Brockhaus F Zhang J Angyalosi G Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial Pediatr Pulmonol 10 20 2010 [Epub ahead of print.]
   Google Scholar
• Bhavsar T Liu M Liu X Cantor J Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia Exp Lung Res 2011 37 9 536 541 21967196
   PubMed Web of Science ®Google Scholar
• Ghannam DE Rodriguez GH Raad II Safdar A Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance Eur J Clin Microbiol Infect Dis 2009 28 3 253 259 18752007
   PubMed Web of Science ®Google Scholar
• Aquino RP Prota L Auriemma G Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells Int J Pharm 2012 426 1–2 100 107 22301426
   PubMed Web of Science ®Google Scholar
• Leong KW Ong S Chee HL Lee W Kwa AL Hypersensitivity pneumonitis due to high-dose colistin aerosol therapy Int J Infect Dis 2010 14 11 e1018 e1019 20947404
   PubMed Web of Science ®Google Scholar
• Wood GC Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia Expert Rev Anti Infect Ther 2011 9 11 993 1000 22029519
   PubMed Web of Science ®Google Scholar
• Lu Q Luo R Bodin L Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Anesthesiology 2012 117 6 1335 1347 23132092
   PubMed Web of Science ®Google Scholar
• Safdar A Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis Eur J Clin Microbiol Infect Dis 2012 31 8 1883 1887 22198679
   PubMed Web of Science ®Google Scholar
• Tsivkovskii R Sabet M Tarazi Z Griffith DC Lomovskaya O Dudley MN Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections FEMS Immunol Med Microbiol 2011 61 2 141 146 21073547
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Papanas N Kioumis I Chatzaki E Maltezos E Zarogoulidis K Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases Eur J Clin Pharmacol 2012 68 5 479 503 22105373
   PubMed Web of Science ®Google Scholar
• Peterson JW Moen ST Healy D Protection afforded by fluoroquinolones in animal models of respiratory infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis Open Microbiol J 2010 4 34 46 21127743
   PubMedGoogle Scholar
• Baldwin DR Honeybourne D Wise R Pulmonary disposition of antimicrobial agents: methodological considerations Antimicrob Agents Chemother 1992 36 6 1171 1175 1416816
   PubMed Web of Science ®Google Scholar
• Wang F Daugherty B Keise LL Heterogeneity of claudin expression by alveolar epithelial cells Am J Respir Cell Mol Biol 2003 29 1 62 70 12600828
   PubMed Web of Science ®Google Scholar
• Campbell L Abulrob AN Kandalaft LE Constitutive expression of P-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures J Pharmacol Exp Ther 2003 304 1 441 452 12490621
   PubMed Web of Science ®Google Scholar
• Fojo AT Ueda K Slamon DJ Poplack DG Gottesman MM Pastan I Expression of a multidrug-resistance gene in human tumors and tissues Proc Natl Acad Sci U S A 1987 84 1 265 269 2432605
   PubMed Web of Science ®Google Scholar
• Zaman GJ Versantvoort CH Smit JJ Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines Cancer Res 1993 53 8 1747 1750 8467491
   PubMed Web of Science ®Google Scholar
• Togami K Chono S Morimoto K Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages Biopharm Drug Dispos 2011 32 7 389 397 21812004
   PubMed Web of Science ®Google Scholar
• Geist LJ Powers LS Monick MM Hunninghake GW Asbestos stimulation triggers differential cytokine release from human monocytes and alveolar macrophages Exp Lung Res 2000 26 1 41 56 10660835
   PubMed Web of Science ®Google Scholar
• Mao JT Roth MD Serio KJ Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers Clin Cancer Res 2003 9 16 Pt 1 5835 5841 14676104
   PubMed Web of Science ®Google Scholar
• Ogle CK Ogle JD Johnson C Keynton L Alexander JW The production of C3, PGE2 and TxB2 by splenic, alveolar, and peritoneal guinea pig macrophages Prostaglandins 1988 36 3 279 289 3237993
   PubMed Web of Science ®Google Scholar
• Rennard SI Hunninghake GW Bitterman PB Crystal RG Production of fbronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases Proc Natl Acad Sci U S A 1981 78 11 7147 7151 6947279
   PubMed Web of Science ®Google Scholar
• Weissbach S Neuendank A Pettersson M Schaberg T Pison U Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages Am J Physiol 1994 267 6 Pt 1 L660 L666 7810671
   PubMed Web of Science ®Google Scholar
• Allen TM Liposomal drug formulations. Rationale for development and what we can expect for the future Drugs 1998 56 5 747 756 9829150
   PubMed Web of Science ®Google Scholar
• Klonne DR Dodd DE Losco PE Troup CM Tyler TR Two-week aerosol inhalation study on polyethylene glycol (PEG) 3350 in F-344 rats Drug Chem Toxicol 1989 12 1 39 48 2714207
   PubMed Web of Science ®Google Scholar
• Zhou L Li Z Liu Z Ren J Qu X Luminescent carbon dot-gated nanovehicles for ph-triggered intracellular controlled release and imaging Langmuir 2013 29 21 6396 6403 23642102
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P Hohenforst-Schmidt W Darwiche K 2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy Gene Ther 5 30 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Gonzalez-Juarrero M Woolhiser LK Brooks E DeGroote MA Lenaerts AJ Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery Antimicrob Agents Chemother 2012 56 7 3957 3959 22547626
   PubMed Web of Science ®Google Scholar
• Ren S Guo LL Yang J Doxycycline attenuates acrolein-induced mucin production, in part by inhibiting MMP-9 Eur J Pharmacol 2011 650 1 418 423 21036164
   PubMed Web of Science ®Google Scholar
• Ward JE Ren R Toraldo G Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis Blood 2011 118 25 6610 6617 21998211
   PubMed Web of Science ®Google Scholar
• Hall IH Schwab UE Ward ES Butts JD Wolford ET Ives TJ Disposition and intracellular activity of azithromycin in human THP-1 acute monocytes Int J Antimicrob Agents 2002 20 5 348 360 12431870
   PubMed Web of Science ®Google Scholar
• Bosquillon C Preat V Vanbever R Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats J Control Release 2004 96 2 233 244 15081215
   PubMed Web of Science ®Google Scholar
• Nemec A Pavlica Z Nemec-Svete A Erzen D Milutinovic A Petelin M Aerosolized clindamycin is superior to aerosolized dexamethasone or clindamycin-dexamethasone combination in the treatment of severe Porphyromonas gingivalis aspiration pneumonia in an experimental murine model Exp Lung Res 2012 38 1 9 18 22149928
   PubMed Web of Science ®Google Scholar
• Hraiech S Bregeon F Brunel JM Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia J Antimicrob Chemother 2012 67 10 2452 2458 22744759
   PubMed Web of Science ®Google Scholar
• Alhanout K Brunel JM Dubus JC Rolain JM Andrieu V Suitability of a new antimicrobial aminosterol formulation for aerosol delivery in cystic fibrosis J Antimicrob Chemother 2011 66 12 2797 2800 21933787
   PubMed Web of Science ®Google Scholar
• Labiris NR Dolovich MB Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications Br J Clin Pharmacol 2003 56 6 600 612 14616419
   PubMed Web of Science ®Google Scholar
• Hess DR Nebulizers: principles and performance Respir Care 2000 45 6 609 622 10894454
   PubMedGoogle Scholar
• Ari A Areabi H Fink JB Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation Respir Care 2010 55 7 837 844 20587094
   PubMed Web of Science ®Google Scholar
• Dhand R Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol Respir Care 2002 47 12 1406 1416 12467499
   PubMedGoogle Scholar
• Abu-Rabie P Denniff P Spooner N Brynjolffssen J Galluzzo P Sanders G Method of applying internal standard to dried matrix spot samples for use in quantitative bioanalysis Anal Chem 2011 83 22 8779 8786 21972889
   PubMed Web of Science ®Google Scholar
• Zierenberg B Optimizing the in vitro performance of Respimat J Aerosol Med 1999 12 Suppl 1 S19 S24 10623337
   PubMedGoogle Scholar
• Dolovich M New propellant-free technologies under investigation J Aerosol Med 1999 12 Suppl 1 S9 S17 10623341
   PubMedGoogle Scholar
• Newman SP Weisz AW Talaee N Clarke SW Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique Thorax 1991 46 10 712 716 1750017
   PubMed Web of Science ®Google Scholar
• Wee WB Leung K Coates AL Modeling breath-enhanced jet nebulizers to estimate pulmonary drug deposition J Aerosol Med Pulm Drug Deliv 3 29 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• McCormack P Southern KW McNamara PS New nebulizer technology to monitor adherence and nebulizer performance in cystic fibrosis J Aerosol Med Pulm Drug Deliv 2012 25 6 307 309 22856641
   PubMed Web of Science ®Google Scholar
• Davis JN Stagg D Interrelationships of the volume and time components of individual breaths in resting man J Physiol 1975 245 2 481 498 1142186
   PubMed Web of Science ®Google Scholar
• Stegen K Neujens A Crombez G Hermans D Van de Woestijne KP Van den Bergh O Negative affect, respiratory reactivity, and somatic complaints in a CO2 enriched air inhalation paradigm Biol Psychol 1998 49 1–2 109 122 9792488
   PubMed Web of Science ®Google Scholar
• Caille V Ehrmann S Boissinot E Perrotin D Diot P Dequin PF Influence of jet nebulization and oxygen delivery on the fraction of inspired oxygen: an experimental model J Aerosol Med Pulm Drug Deliv 2009 22 3 255 261 19466907
   PubMed Web of Science ®Google Scholar
• Vecellio L Abdelrahim ME Montharu J Galle J Diot P Dubus JC Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin J Cyst Fibros 2011 10 2 86 92 21075063
   PubMed Web of Science ®Google Scholar
• Coates AL Green M Leung K A comparison of amount and speed of deposition between the PARI LC STAR(R) jet nebulizer and an investigational eFlow(R) nebulizer J Aerosol Med Pulm Drug Deliv 2011 24 3 157 163 21361784
   PubMed Web of Science ®Google Scholar
• Tiemersma S Minocchieri S Lingen RA Nelle M Devadason SG Vibrating membrane devices deliver aerosols more efficient than standard devices: a study in a neonatal upper airway model J Aerosol Med Pulm Drug Deliv 10 28 2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Nemoto M Hiki Y Shimada K Novel hormonal delivery method using the ink-jet technology: application to pulmonary insulin therapies Diabetes Technol Ther 2011 13 5 509 517 21406017
   PubMed Web of Science ®Google Scholar
• Pitance L Reychler G Leal T Aerosol delivery to the lung is more efficient using an extension with a standard jet nebulizer than an open-vent jet nebulizer J Aerosol Med Pulm Drug Deliv 2013 26 4 208 214 23286829
   PubMed Web of Science ®Google Scholar
• Pitance L Vecellio L Leal T Reychler G Reychler H Liistro G Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations J Aerosol Med Pulm Drug Deliv 2010 23 6 389 396 20958144
   PubMed Web of Science ®Google Scholar
• Rao N Kadrichu N Ament B Application of a droplet evaporation model to aerodynamic size measurement of drug aerosols generated by a vibrating mesh nebulizer J Aerosol Med Pulm Drug Deliv 2010 23 5 295 302 20455771
   PubMed Web of Science ®Google Scholar
• Skaria S Smaldone GC Omron NE U22: comparison between vibrating mesh and jet nebulizer J Aerosol Med Pulm Drug Deliv 2010 23 3 173 180 20500093
   PubMed Web of Science ®Google Scholar
• Fadl A Wang J Zhang Z Metered-dose inhaler efficiency enhancement: a case study and novel design Inhal Toxicol 2010 22 7 601 609 20387999
   PubMed Web of Science ®Google Scholar
• Standaert TA Vandevanter D Ramsey BW The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer J Aerosol Med 2000 13 2 147 153 11010595
   PubMedGoogle Scholar
• Hurley PK Smye SW Cunliffe H Assessment of antibiotic aerosol generation using commercial jet nebulizers J Aerosol Med 1994 7 3 217 228 10150480
   PubMedGoogle Scholar
• Rottier BL de Boer AH Duiverman EJ Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: three areas for future research. Which areas to target? Which particle size to deliver? Which device to use? J Cyst Fibros 2010 9 4 296 297 20435528
   PubMed Web of Science ®Google Scholar
• Rubin BK Aerosolized antibiotics for non-cystic fibrosis bronchiectasis J Aerosol Med Pulm Drug Deliv 2008 21 1 71 76 18518833
   PubMed Web of Science ®Google Scholar
• Dhand R Aerosol delivery during mechanical ventilation: from basic techniques to new devices J Aerosol Med Pulm Drug Deliv 2008 21 1 45 60 18518831
   PubMed Web of Science ®Google Scholar
• el Din MA Palmer LB el Tayeb MN Khalil I Gabr MS Nebulizer therapy with antibiotics in chronic suppurative lung disease J Aerosol Med 1994 7 4 345 350 10150487
   PubMedGoogle Scholar
• Lange CF Finlay WH Liquid atomizing: nebulizing and other methods of producing aerosols J Aerosol Med 2006 19 1 28 35 16551212
   PubMedGoogle Scholar
• Hasan MA Lange CF Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics J Aerosol Med 2007 20 3 282 293 17894535
   PubMedGoogle Scholar
• Britland S Finter W Chrystyn H Eagland D Abdelrahim ME Droplet aerodynamics, cellular uptake, and efficacy of a nebulizable corticosteroid nanosuspension are superior to a micronized dosage form Biotechnol Prog 2012 28 5 1152 1159 22887984
   PubMed Web of Science ®Google Scholar
• Diot P Dequin PF Rivoire B Aerosols and anti-infectious agents J Aerosol Med 2001 14 1 55 64 11495486
   PubMedGoogle Scholar
• Lo D VanDevanter DR Flume P Smyth A Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med 2011 105 Suppl 2 S9 S17 22208548
   PubMed Web of Science ®Google Scholar
• Todisco T Eslami A Baglioni S Basis for nebulized antibiotics: droplet characterization and in vitro antimicrobial activity versus Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa J Aerosol Med 2000 13 1 11 16 10947319
   PubMedGoogle Scholar
• Takanami C Goto Y Physical properties of antibiotic aerosols produced by jet and ultrasonic nebulizers J Aerosol Med 1990 3 1 45 52 10147674
   PubMedGoogle Scholar
• Ruddy J Emerson J Moss R Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin J Aerosol Med Pulm Drug Deliv 2013 26 2 69 75 22620494
   PubMed Web of Science ®Google Scholar